Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disorder that involves more than one phenotype associated with the central nervous system, including but not limited to intellectual disability, autism, and seizures (epilepsy).
No HPO annotations are available for this condition.
Age of onset: newborn period, before birth, childhood, adulthood, infancy, at birth.
The clinical phenotype of GRIA2-related neurodevelopmental disorder (GRIA2-NDD) comprises global developmental delay, cognitive and language impairment with poor or absent speech in almost all individuals, and varying combinations of tone abnormalities at birth, early-onset developmental and epileptic encephalopathy, complex movement disorders with or without epilepsy, and neurobehavioral and/or psychiatric disorders. Some affected individuals have normal early development, followed by variable regression with impaired social and/or language skills. About half of individuals are nonverbal. Several individuals are unable to walk, and several have gait abnormalities, including gait dyspraxia and ataxia.
Formal diagnostic criteria for GRIA2-related neurodevelopmental disorder (NDD) have not been established.
GRIA2-NDD should be considered in a proband with the following clinical and brain MRI findings and family history.
Clinical findings
Developmental delay (DD) and/or intellectual disability (ID) (present in all individuals)
No approved treatments are currently available for complex neurodevelopmental disorder. The disease remains an area of unmet medical need.
No clinical practice guidelines for GRIA2-related neurodevelopmental disorder (GRIA2-NDD) have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with GRIA2-NDD and similar disorders.
To establish the extent of disease and needs in an individual diagnosed with GRIA2-NDD, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended.
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended.
Table 6.
GRIA2-Related Neurodevelopmental Disorder: Recommended Surveillance
System/Concern | Evaluation | Frequency
| • Measurement of growth parameters (incl OFC)
2 clinical trials registered. Interventions under study include other interventions. Pipeline includes 2 NA. Research is primarily sponsored by academic and government institutions.
122 publications have been identified in PubMed for complex neurodevelopmental disorder. Research spans Basic Science / Preclinical (39%), Review / Meta-Analysis (20%), and Epidemiology / Natural History (12%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 48 |
Data assembled from 5 of 12 sources · Last updated Sep 17, 2026, 7:22 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about complex neurodevelopmental disorder
Source: GeneReviews — "GRIA2-Related Neurodevelopmental Disorder"
• Body tone abnormalities
Source: GeneReviews — "GRIA2-Related Neurodevelopmental Disorder"
Because GRIA2-related neurodevelopmental disorder is associated with a broad phenotypic spectrum, all disorders with intellectual disability without other distinctive clinical features or findings should be considered in the differential diagnosis. See OMIM Autosomal Dominant, Autosomal Recessive, Nonsyndromic X-Linked, and Syndromic X-Linked Intellectual Developmental Disorder Phenotypic Series. In persons with abnormal developmental milestones, epilepsy, and features resembling MECP2 disorders, the genes listed in may be of specific interest. Table 3. Selected Genes of Interest in the Differential Diagnosis of GRIA2-Related Neurodevelopmental Disorder
Gene | Disorder | MOI |
|---|---|---|
FOXG1 | Rett syndrome, congenital variant (See FOXG1 Syndrome.) | AD |
GRIA1 | GRIA1-NDD (OMIM 619931, 619927) | ADAR |
GRIA3 | GRIA3-NDD (OMIM 300699) | XL |
GRIA4 | GRIA4-NDD (OMIM 617864) | AD GRIN1 |
GRIN2A | GRIN2A-NDD (See GRIN2A-Related Speech Disorders and Epilepsy.) | AD MECP2 |
Source: GeneReviews — "GRIA2-Related Neurodevelopmental Disorder"
Biomarker and diagnostic research for complex neurodevelopmental disorder has been reported in the published literature.
Table 4.
GRIA2-Related Neurodevelopmental Disorder: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Measure length/height, weight, OFC |
| Neurologic eval | To include:
Brain MRI
EEG if history of seizures
Eval for movement disorders
Eval for sleep apnea
| Developmental assessment/ physical medicine rehab/ PT OT eval | To include assessment of:
Motor, adaptive, cognitive, speech-language ability
Mobility, ADL, need for adaptive devices
Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills
Early intervention/ special education
Speech therapy
| Eval by speech-language therapist | Consider need for augmentative alternative communication (AAC)
Neurobehavioral/
| Neuropsychiatric eval | For persons age 12 mos: screening for behavior concerns including ADHD, ASD
| Orthopedics/ physical medicine rehab/ PT OT eval | To include assessment ...
Source: GeneReviews — "GRIA2-Related Neurodevelopmental Disorder"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "GRIA2-Related Neurodevelopmental Disorder"
2 trials found
Eval of nutritional status safety of oral intake
| At each visit
| • Monitor for constipation gastroesophageal reflux disease.
Monitor feeding needs, esp in early infancy.
| Monitor for evidence of aspiration, respiratory insufficiency, or abnormal respiratory pattern (episodes of hyperventilation).
| • Monitor those w/seizures as clinically indicated.
Assess for new manifestations such as seizures, changes in tone, or movement disorders.
| Monitor developmental progress educational needs.
Neurobehavioral/
| Behavioral assessment for anxiety, ADHD, ASD, aggression, self-injury
| Physical medicine, OT/PT assessment of mobility, self-help skills
| Monitor those w/abnormal ocular motility or strabismus. | Per treating ophthalmologist(s)
| Monitor abnormal breathing patterns (irregular breathing hyperventilation episodes). | At each visit
| Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family...
Source: GeneReviews — "GRIA2-Related Neurodevelopmental Disorder"
Estimated prevalence: Unknown (Unknown prevalence).
Research summaries | 25 | 20% |
Disease patterns and progression | 15 | 12% |
New treatment approaches | 13 | 11% |
Testing and diagnosis research | 8 | 7% |
Patient case studies | 7 | 6% |
Clinical study results | 4 | 3% |
Other research | 2 | 2% |
Fan F (2026). [PMID: 42071249](https://pubmed.ncbi.nlm.nih.gov/42071249/). *Syst Rev*. [Review / Meta-Analysis]
Sun Y (2026). [PMID: 41886894](https://pubmed.ncbi.nlm.nih.gov/41886894/). *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*. [Basic Science / Preclinical]
Ojha SK (2026). [PMID: 41741707](https://pubmed.ncbi.nlm.nih.gov/41741707/). *Molecular psychiatry*. [Clinical Trial Publication]
Peñalba F (2026). [PMID: 41952964](https://pubmed.ncbi.nlm.nih.gov/41952964/). *Front Microbiomes*. [Epidemiology / Natural History]
Aral A (2026). [PMID: 41496615](https://pubmed.ncbi.nlm.nih.gov/41496615/). *Journal of attention disorders*. [Gene Therapy / Novel Therapeutics]
Fan YS (2026). [PMID: 41253019](https://pubmed.ncbi.nlm.nih.gov/41253019/). *Schizophrenia research*. [Diagnostic / Biomarker]
Yu WX (2026). [PMID: 41889432](https://pubmed.ncbi.nlm.nih.gov/41889432/). *Digit Health*. [Diagnostic / Biomarker]
Başkaya GD (2026). [PMID: 41886646](https://pubmed.ncbi.nlm.nih.gov/41886646/). *International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience*. [Epidemiology / Natural History]
Planas-Serra L (2026). [PMID: 41935529](https://pubmed.ncbi.nlm.nih.gov/41935529/). *American journal of human genetics*. [Basic Science / Preclinical]
Saeliw T (2026). [PMID: 42196145](https://pubmed.ncbi.nlm.nih.gov/42196145/). *Int J Mol Sci*. [Basic Science / Preclinical]
AI-curated news mentioning complex neurodevelopmental disorder
Updated Jun 4, 2026
There are currently no approved treatments for the disease. "Advances in gene therapy and CNS-targeted delivery technologies are creating new opportunities to develop potential treatments for complex neurodevelopmental disorders like Kleefstra syndrome," said Dr. ATLANTA, June 3, 2026 /PRNewswire/ -- IDefine – The Kleefstra Syndrome Foundation, a leading patient advocacy organization, today announced a collaboration with UT Southwestern Medical Center to advance development of a potential gene therapy to treat Kleefstra syndrome (KS), a rare neurodevelopmental disorder caused by changes or loss of the EHMT1 gene, which plays a critical role in brain development and function. - Dr. Steven Gray will lead research effort focused on potential therapy to replace the EHMT1 gene in patients with rare neurodevelopmental disorder View original content:https://www.prnewswire.com/news-releases/idefine-and-ut-southwestern-announce-research-collaboration-to-advance-gene-therapy-for-rare-disease-kleefstra-syndrome-302789121.html The two-year research program, led by Steven Gray, PhD, professor at UT Southwestern and director of the UTSW Gene Therapy Program, will evaluate the feasibility and safety of EHMT1 gene replacement therapy using next-generation gene delivery technology designed to target the central nervous system (CNS). "This landmark research collaboration represents a meaningful step forward in our mission to accelerate research that can lead to a first treatment for Kleefstra syndrome," said Eric Scheeff, PhD, chief scientific officer of IDefine. "We are especially honored to support and partner with Dr. Steven Gray and the UT Southwestern Gene Therapy Program in this effort.